Is RCT (Reverse Cholesterol Transport) Ready for an RCT (Randomized Controlled Trial)?

TY - JOUR

T1 - Is RCT (Reverse Cholesterol Transport) Ready for an RCT (Randomized Controlled Trial)?

AU - Nambi, Vijay

AU - Rohatgi, Anand K

AU - Bhatt, Deepak L.

N1 - Funding Information: The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs. Dr. Nambi has been a principal investigator of a study sponsored by Merck; event adjudicator for a study sponsored by Siemens Diagnostics; and holds a provisional patent along with Baylor College of Medicine and Roche on “Use of biomarkers in prediction of heart failure.” Dr. Rohatgi is supported by National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) grant R01HL136724, NIH/NHLBI grant R21HL137450, and American Heart Association grant 17UNPG33840006; has received a research grant from Merck; has been a consultant for Merck and CSL; and has served on an advisory board for HDL Diagnostics. Dr. Bhatt has served on the advisory boards of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; has served on the board of directors of the Boston VA Research Institute, the Society of Cardiovascular Patient Care, and TobeSoft; served as chair of the American Heart Association Quality Oversight Committee; has served on data monitoring committees for the Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, and Population Health Research Institute; has received honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org ), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor; associate editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (CME steering committees); has other relationships with Clinical Cardiology (deputy editor), NCDR-ACTION Registry Steering Committee (chair), and VA CART Research and Publications Committee (chair); has received research funding from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi, and The Medicines Company; has received royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); has been a site coinvestigator for Biotronik, Boston Scientific, and St. Jude Medical (now Abbott); has been a trustee for the American College of Cardiology; and has performed unfunded research for FlowCo, Merck, Novo Nordisk, PLx Pharma, and Takeda.

PY - 2018/12/25

Y1 - 2018/12/25

KW - atherosclerosis

KW - high-density lipoprotein cholesterol

KW - reverse cholesterol transport

UR - http://www.scopus.com/inward/record.url?scp=85057718481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057718481&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2018.10.034

DO - 10.1016/j.jacc.2018.10.034

M3 - Editorial

C2 - 30573029

AN - SCOPUS:85057718481

SN - 0735-1097

VL - 72

SP - 3270

EP - 3273

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 25

ER -